Photocure ASA
Photocure ASA (0IMT.L) Financial Performance & Income Statement Overview
Review Photocure ASA (0IMT.L) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Photocure ASA (0IMT.L) Income Statement & Financial Overview
Analyze Photocure ASA’s 0IMT.L earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $125.33M | $141.68M | $120.22M | $145.45M |
| Cost of Revenue | $9.14M | $7.49M | $7.86M | $14.82M |
| Gross Profit | $116.19M | $134.19M | $112.37M | $130.63M |
| Gross Profit Ratio | $0.93 | $0.95 | $0.93 | $0.90 |
| R&D Expenses | $1.17M | $104000.00 | $1.64M | $1.10M |
| SG&A Expenses | $89.66M | $98.11M | $83.88M | $87.002M |
| Operating Expenses | $121.77M | $133.009M | $112.37M | $95.30M |
| Total Costs & Expenses | $130.91M | $140.50M | $122.41M | $102.92M |
| Interest Income | $5.20M | $6.23M | $6.90M | $5.24M |
| Interest Expense | $9.01M | $6.24M | $9.65M | $9.73M |
| Depreciation & Amortization | $7.39M | $7.27M | $7.21M | $7.19M |
| EBITDA | $7.02M | $14.69M | $11.93M | $27.85M |
| EBITDA Ratio | $0.06 | $0.10 | $0.10 | $0.19 |
| Operating Income | -$5.58M | $1.18M | -$2.19M | $42.52M |
| Operating Income Ratio | -$0.04 | $0.008 | -$0.02 | $0.29 |
| Other Income/Expenses (Net) | -$3.81M | -$8000.00 | -$2.76M | -$26.36M |
| Income Before Tax | -$9.39M | $1.18M | -$4.94M | $16.16M |
| Income Before Tax Ratio | -$0.07 | $0.008 | -$0.04 | $0.11 |
| Income Tax Expense | -$6.97M | $6.96M | -$1.48M | $3.83M |
| Net Income | -$2.41M | -$5.79M | -$3.47M | $12.33M |
| Net Income Ratio | -$0.02 | -$0.04 | -$0.03 | $0.08 |
| EPS | -$0.09 | -$0.21 | -$0.13 | $0.45 |
| Diluted EPS | -$0.09 | -$0.21 | -$0.13 | $0.45 |
| Weighted Avg Shares Outstanding | $26.83M | $27.55M | $27.11M | $27.40M |
| Weighted Avg Shares Outstanding (Diluted) | $26.83M | $27.55M | $27.11M | $27.40M |
The company's financials show resilient growth, with revenue advancing from $145.45M in Q2 2024 to $125.33M in Q1 2025. Gross profit remained healthy with margins at 93% in Q1 2025 compared to 90% in Q2 2024. Operating income hit -$5.58M last quarter, sustaining a consistent -4% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $7.02M. Net income rose to -$2.41M, while earnings per share reached -$0.09. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan